| 出品公司: | ZYbscience |
|---|---|
| 载体名称: | pSP64 |
| 质粒类型: | 酵母双杂交系统载体 |
| 高拷贝/低拷贝: | 高拷贝 |
| 启动子: | -- |
| 克隆方法: | 多克隆位点,限制性内切酶 |
| 载体大小: | 2999bp |
| 5' 测序引物及序列: | Sp6 Fwd: ATTTAGGTGACACTATAG |
| 3' 测序引物及序列: | -- |
| 载体标签: | -- |
| 载体抗性: | 氨苄青霉素(Ampicillian) |
| 筛选标记: | -- |
| 备注: | -- |
| 产品目录号: | -- |
| 稳定性: | 瞬表达 |
| 组成型: | 组成型 |
| 病毒/非病毒: | 非病毒 |
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
-20℃低温保存
- 保质期:
三年
- 英文名:
pSP64
- 库存:
20
- 供应商:
泽叶生物
载体基本信息
载体质粒图谱和多克隆位点信息
载体简介
The pSP64 Poly(A) Vector can be used as a standard cloning vector and for in vitro transcription
from the SP6 promoter. The pSP64 Poly(A) Vector also can be used to generate poly(A)+ transcripts
in vitro. The vector has a stretch of 30 dA:dT residues inserted between the SacI and EcoRI sites.
Therefore, when foreign DNA is cloned into any polylinker site other than EcoRI (HindIII, PstI, SalI,
AccI, HincII, XbaI, BamHI, AvaI, SmaI or SacI), linearization of the recombinant plasmid with EcoRI
allows the use of SP6 RNA polymerase in vitro to prepare RNA copies of the inserted sequences that
contain a synthetic 3′ "poly(A)" tail of 30 residues.
载体序列
LOCUS pSP64 2999 bp DNA SYN
DEFINITION pSP64
ACCESSION
KEYWORDS
SOURCE
ORGANISM other sequences; artificial sequences; vectors.
FEATURES Location/Qualifiers
source 1..2999
/organism="pSP64"
/mol_type="other DNA"
promoter complement(63..81)
/label="M13_reverse_primer"
misc_feature complement(80..102)
/label="M13_pUC_rev_primer"
promoter complement(116..145)
/label="lac_promoter"
gene complement(1228..2088)
/label="Ampicillin"
/gene="Ampicillin"
CDS complement(1228..2088)
/label="ORF frame 3"
/translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGY
IELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRIDAGQEQLGRRIHYSQNDLVE
YSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRL
DRWEPELNEAIPNDERDTTMPVAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPL
LRSALPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIA
EIGASLIKHW*"
promoter complement(2130..2158)
/label="AmpR_promoter"
/translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGY
IELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRIDAGQEQLGRRIHYSQNDLVE
YSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRL
DRWEPELNEAIPNDERDTTMPVAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPL
LRSALPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIA
EIGASLIKHW*"
misc_feature complement(2317..2339)
/label="pGEX_3_primer"
/translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGY
IELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRIDAGQEQLGRRIHYSQNDLVE
YSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRL
DRWEPELNEAIPNDERDTTMPVAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPL
LRSALPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIA
EIGASLIKHW*"
gene complement(2490..2741)
/label="tet (887 - 636)"
/gene="tet (887 - 636)"
/translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGY
IELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRIDAGQEQLGRRIHYSQNDLVE
YSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRL
DRWEPELNEAIPNDERDTTMPVAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPL
LRSALPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIA
EIGASLIKHW*"
misc_feature 2673..2692
/label="pBRrevBam_primer"
/translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGY
IELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRIDAGQEQLGRRIHYSQNDLVE
YSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRL
DRWEPELNEAIPNDERDTTMPVAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPL
LRSALPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIA
EIGASLIKHW*"
misc_feature 2983..1
/label="Sp6_primer"
/translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGY
IELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRIDAGQEQLGRRIHYSQNDLVE
YSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRL
DRWEPELNEAIPNDERDTTMPVAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPL
LRSALPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIA
EIGASLIKHW*"
ORIGIN
1 gaatacaagc ttgggctgca ggtcgactct agaggatccc cgggcgagct cgaattcgta
61 atcatggtca tagctgtttc ctgtgtgaaa ttgttatccg ctcacaattc cacacaacat
121 acgagccgga agcataaagt gtaaagcctg gggtgcctaa tgagtgagct aactcacatt
181 aattgcgttg cgctcactgc ccgctttcca gtcgggaaac ctgtcgtgcc agctgcatta
241 atgaatcggc caacgcgcgg ggagaggcgg tttgcgtatt gggcgctctt ccgcttcctc
301 gctcactgac tcgctgcgct cggtcgttcg gctgcggcga gcggtatcag ctcactcaaa
361 ggcggtaata cggttatcca cagaatcagg ggataacgca ggaaagaaca tgtgagcaaa
421 aggccagcaa aaggccagga accgtaaaaa ggccgcgttg ctggcgtttt tccataggct
481 ccgcccccct gacgagcatc acaaaaatcg acgctcaagt cagaggtggc gaaacccgac
541 aggactataa agataccagg cgtttccccc tggaagctcc ctcgtgcgct ctcctgttcc
601 gaccctgccg cttaccggat acctgtccgc ctttctccct tcgggaagcg tggcgctttc
661 tcatagctca cgctgtaggt atctcagttc ggtgtaggtc gttcgctcca agctgggctg
721 tgtgcacgaa ccccccgttc agcccgaccg ctgcgcctta tccggtaact atcgtcttga
781 gtccaacccg gtaagacacg acttatcgcc actggcagca gccactggta acaggattag
841 cagagcgagg tatgtaggcg gtgctacaga gttcttgaag tggtggccta actacggcta
901 cactagaagg acagtatttg gtatctgcgc tctgctgaag ccagttacct tcggaaaaag
961 agttggtagc tcttgatccg gcaaacaaac caccgctggt agcggtggtt tttttgtttg
1021 caagcagcag attacgcgca gaaaaaaagg atctcaagaa gatcctttga tcttttctac
1081 ggggtctgac gctcagtgga acgaaaactc acgttaaggg attttggtca tgagattatc
1141 aaaaaggatc ttcacctaga tccttttaaa ttaaaaatga agttttaaat caatctaaag
1201 tatatatgag taaacttggt ctgacagtta ccaatgctta atcagtgagg cacctatctc
1261 agcgatctgt ctatttcgtt catccatagt tgcctgactc cccgtcgtgt agataactac
1321 gatacgggag ggcttaccat ctggccccag tgctgcaatg ataccgcgag acccacgctc
1381 accggctcca gatttatcag caataaacca gccagccgga agggccgagc gcagaagtgg
1441 tcctgcaact ttatccgcct ccatccagtc tattaattgt tgccgggaag ctagagtaag
1501 tagttcgcca gttaatagtt tgcgcaacgt tgttgccatt gctacaggca tcgtggtgtc
1561 acgctcgtcg tttggtatgg cttcattcag ctccggttcc caacgatcaa ggcgagttac
1621 atgatccccc atgttgtgca aaaaagcggt tagctccttc ggtcctccga tcgttgtcag
1681 aagtaagttg gccgcagtgt tatcactcat ggttatggca gcactgcata attctcttac
1741 tgtcatgcca tccgtaagat gcttttctgt gactggtgag tactcaacca agtcattctg
1801 agaatagtgt atgcggcgac cgagttgctc ttgcccggcg tcaatacggg ataataccgc
1861 gccacatagc agaactttaa aagtgctcat cattggaaaa cgttcttcgg ggcgaaaact
1921 ctcaaggatc ttaccgctgt tgagatccag ttcgatgtaa cccactcgtg cacccaactg
1981 atcttcagca tcttttactt tcaccagcgt ttctgggtga gcaaaaacag gaaggcaaaa
2041 tgccgcaaaa aagggaataa gggcgacacg gaaatgttga atactcatac tcttcctttt
2101 tcaatattat tgaagcattt atcagggtta ttgtctcatg agcggataca tatttgaatg
2161 tatttagaaa aataaacaaa taggggttcc gcgcacattt ccccgaaaag tgccacctga
2221 cgtctaagaa accattatta tcatgacatt aacctataaa aataggcgta tcacgaggcc
2281 ctttcgtctc gcgcgtttcg gtgatgacgg tgaaaacctc tgacacatgc agctcccgga
2341 gacggtcaca gcttgtctgt aagcggatgc cgggagcaga caagcccgtc agggcgcgtc
2401 agcgggtgtt ggcgggtgtc ggggctggct taactatgcg gcatcagagc agattgtact
2461 gagagtgcac catatcgacg ctctccctta tgcgactcct gcattaggaa gcagcccagt
2521 agtaggttga ggccgttgag caccgccgcc gcaaggaatg gtgcatgcaa ggagatggcg
2581 cccaacagtc ccccggccac ggggcctgcc accataccca cgccgaaaca agcgctcatg
2641 agcccgaagt ggcgagcccg atcttcccca tcggtgatgt cggcgatata ggcgccagca
2701 accgcacctg tggcgccggt gatgccggcc acgatgcgtc cggcgtagag gatctggcta
2761 gcgatgaccc tgctgattgg ttcgctgacc atttccgggg tgcggaacgg cgttaccaga
2821 aactcagaag gttcgtccaa ccaaaccgac tctgacggca gtttacgaga gagatgatag
2881 ggtctgcttc agtaagccag atgctacaca attaggcttg tacatattgt cgttagaacg
2941 cggctacaat taatacataa ccttatgtat catacacata cgatttaggt gacactata
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Salmonella Phages and ProphagesGenomics and Practical Aspects
that these viruses fall into five groupings (P27-like, P2-like, lambdoid, P22-like, and T7-like) and three outliers (ɛ15, KS7, and Felix O1). The P27 group is only represented by ST64B; the P2 group contains Fels-2, SopEφ, and PSP3; the lambdoid Salmonella phages
forpSilencer3.1-H1hygroM13F(-47)3.0REVpSilencer4_1-CMVneopSilener4.1-5'CMV-ProforpSILENCEV2.0-U6T72.0REVpSIneoT7EBVrev,T3PsitT7T7TpSK01-TM13FM13RpSK-CMV(KAN+)T7T3pSOSPsos5'Psos3'pSP64SP6M13revpSP64/65SP6此载体无反向引物pSP65SP6M13revpSP70SP6T7pSP71SP6T7pSP72SP6T7pSP73
目前慢病毒载体主要应用在以下几个方面: 细胞基因治疗(截止目前,已上市的 CAR-T 产品有 9 款采用了慢病毒载体递送 CAR 基因) 基因表达调控(过表达、RNA 干扰研究等) 基因编辑(CRlSPR/Cas9 gRNA 文库筛选、基因敲除、敲入、点突变、基因激活/抑制) 稳转细胞株构建 活体细胞成像追踪 转基因动物 图 1 慢病毒载体的主要应用方向 应用案例 案例 1:用慢病毒载体进行基因过表达,构建稳转细胞株,研究葡萄糖激酶在前列腺癌(PCa)中的作用[1] 细胞
技术资料暂无技术资料 索取技术资料








